Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies

[1]  Zhaoqin Huang,et al.  TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism , 2022, Cancer Immunology, Immunotherapy.

[2]  Stephanie Ma,et al.  Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications , 2022, Hepatology.

[3]  David Landeira,et al.  EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization , 2022, Oncogene.

[4]  Lin Zhao,et al.  Noncoding RNAs related to the hedgehog pathway in cancer: clinical implications and future perspectives , 2022, Molecular cancer.

[5]  Feimeng Zheng,et al.  NDR1 increases NOTCH1 signaling activity by impairing Fbw7 mediated NICD degradation to enhance breast cancer stem cell properties , 2022, Molecular medicine.

[6]  Runyu Yang,et al.  Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction , 2022, Molecular medicine.

[7]  Jian Zhang,et al.  Cell plasticity in patients with NSCLC: The controversial origins of transformed SCLC. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  Chuxia Deng,et al.  Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance , 2022, International journal of biological sciences.

[9]  H. Cui,et al.  Epigenetic modification regulates tumor progression and metastasis through EMT (Review) , 2022, International journal of oncology.

[10]  Jing Zhong,et al.  Wnt signaling in triple-negative breast cancers: Its roles in molecular subtyping and cancer cell stemness and its crosstalk with non-coding RNAs. , 2022, Life sciences.

[11]  Yingyan Yu.  Multi-target combinatory strategy to overcome tumor immune escape , 2022, Frontiers of Medicine.

[12]  M. Di Nicola,et al.  BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer , 2022, Cellular Oncology.

[13]  S. Dalle,et al.  Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma , 2022, Frontiers in Immunology.

[14]  M. Cieśla,et al.  Heme Oxygenase-1 Has a Greater Effect on Melanoma Stem Cell Properties Than the Expression of Melanoma-Initiating Cell Markers , 2022, International journal of molecular sciences.

[15]  Min Jeong Kim,et al.  Reduced HIF-1α Stability Induced by 6-Gingerol Inhibits Lung Cancer Growth through the Induction of Cell Death , 2022, Molecules.

[16]  V. A. Flørenes,et al.  AXL inhibition improves BRAF-targeted treatment in melanoma , 2022, Scientific Reports.

[17]  Susan E. Murray,et al.  Androgen receptor activity in T cells limits checkpoint blockade efficacy , 2022, Nature.

[18]  J. Sun,et al.  Bioengineered Platelets Combining Chemotherapy and Immunotherapy for Postsurgical Melanoma Treatment: Internal Core-Loaded Doxorubicin and External Surface-Anchored Anti-PD-L1 Antibody Backpacks. , 2022, Nano letters.

[19]  Zhigang Wang,et al.  Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy , 2022, Theranostics.

[20]  Gaurav Kumar,et al.  Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma , 2022, Nature Communications.

[21]  David Landeira,et al.  EZH2 endorses cell plasticity to carcinoma cells facilitating mesenchymal to epithelial transition and tumour colonization , 2022, bioRxiv.

[22]  C. Ung,et al.  Uncovering Pharmacological Opportunities for Cancer Stem Cells—A Systems Biology View , 2022, Frontiers in Cell and Developmental Biology.

[23]  Y. Zhu,et al.  Regulation of cancer stem cell activity by thyroid hormone receptor β , 2022, Oncogene.

[24]  E. Giovannetti,et al.  Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma , 2022, Expert review of clinical pharmacology.

[25]  M. Ji,et al.  Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC. , 2022, Future oncology.

[26]  Jianxun Song,et al.  eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma , 2022, Journal for ImmunoTherapy of Cancer.

[27]  M. Ouellette,et al.  Cell Signaling Pathways That Promote Radioresistance of Cancer Cells , 2022, Diagnostics.

[28]  M. Honda,et al.  Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma , 2022, International journal of molecular sciences.

[29]  J. Schlom,et al.  Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication , 2022, The Journal of clinical investigation.

[30]  Hezi Zhang,et al.  Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer , 2022, Frontiers in Genetics.

[31]  Y. Zhuang,et al.  Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling , 2022, Communications Biology.

[32]  F. Lang,et al.  Disruption of DNA Repair and Survival Pathways through Heat Shock Protein inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation therapy. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  M. Bhasin,et al.  Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer. , 2022, Cancer research.

[34]  K. Pantel,et al.  Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation , 2022, Journal of Experimental & Clinical Cancer Research.

[35]  Xiaobei Liu,et al.  HNRNPA2B1 inhibited SFRP2 and activated Wnt-β/catenin via m6A-mediated miR-106b-5p processing to aggravate stemness in lung adenocarcinoma. , 2022, Pathology, research and practice.

[36]  A. Scarpa,et al.  Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance , 2022, Biomedicines.

[37]  K. Yu,et al.  Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer , 2022, Acta Pharmacologica Sinica.

[38]  Marek J. Łos,et al.  Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma , 2022, International journal of molecular sciences.

[39]  A. Friedman,et al.  Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model , 2022, PloS one.

[40]  I. Tinhofer,et al.  Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma , 2022, International journal of molecular sciences.

[41]  K. Ye,et al.  Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis , 2021, Cellular and Molecular Bioengineering.

[42]  Shizhi Wang,et al.  Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers , 2022, Frontiers in Genetics.

[43]  R. Taneja,et al.  EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms , 2021, The FEBS journal.

[44]  S. Okazaki,et al.  MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer , 2021, Cancer science.

[45]  E. Van Cutsem,et al.  The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer , 2021, Nature.

[46]  G. Johnson,et al.  Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition , 2021, The Journal of biological chemistry.

[47]  Shuyi Wang,et al.  EMT‐cancer cells‐derived exosomal miR‐27b‐3p promotes circulating tumour cells‐mediated metastasis by modulating vascular permeability in colorectal cancer , 2021, Clinical and translational medicine.

[48]  M. Kudo,et al.  Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. , 2021, Journal of hepatology.

[49]  F. Rojo,et al.  Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer , 2021, International Journal of Molecular Sciences.

[50]  Meijuan Huang,et al.  Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation , 2021, Frontiers in Oncology.

[51]  Hongjuan You,et al.  Cellular retinol binding protein-1 inhibits cancer stemness via upregulating WIF1 to suppress Wnt/β-catenin pathway in hepatocellular carcinoma , 2021, BMC Cancer.

[52]  G. Christofori,et al.  Distinct contributions of partial and full EMT to breast cancer malignancy. , 2021, Developmental cell.

[53]  G. Sethi,et al.  Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways , 2021, Journal of hepatocellular carcinoma.

[54]  E. Obermayr,et al.  Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer , 2021, Journal of Personalized Medicine.

[55]  Yuchen Liu,et al.  Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. , 2021, Journal of hepatology.

[56]  C. Rudin,et al.  Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation , 2021, Journal of Hematology & Oncology.

[57]  Bin Yu.  Faculty Opinions recommendation of Targeting lysosomal degradation pathways: new strategies and techniques for drug discovery. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[58]  J Zhang,et al.  Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial , 2021, Signal Transduction and Targeted Therapy.

[59]  Xueda Hu,et al.  Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. , 2021, Cancer cell.

[60]  R. Tao,et al.  PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers , 2021, Frontiers in Immunology.

[61]  Zhijie Kang,et al.  Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma , 2021, Signal Transduction and Targeted Therapy.

[62]  T. Shimamura,et al.  A mixture-of-experts deep generative model for integrated analysis of single-cell multiomics data , 2021, Cell reports methods.

[63]  G. Brandi,et al.  First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges , 2021, Expert review of gastroenterology & hepatology.

[64]  H. Beltran,et al.  Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis , 2021, npj Precision Oncology.

[65]  Q. Zhan,et al.  MAGE‐C3 promotes cancer metastasis by inducing epithelial‐mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma , 2021, Cancer communications.

[66]  N. Magné,et al.  Involvement of HIF-1α in the Detection, Signaling, and Repair of DNA Double-Strand Breaks after Photon and Carbon-Ion Irradiation , 2021, Cancers.

[67]  H. Nishizawa,et al.  The transcription factor BACH1 at the crossroads of cancer biology: From epithelial–mesenchymal transition to ferroptosis , 2021, The Journal of biological chemistry.

[68]  H. Tagawa,et al.  Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma , 2021, Cancer science.

[69]  Yuzhuo Wang,et al.  Molecular events in neuroendocrine prostate cancer development , 2021, Nature Reviews Urology.

[70]  R. Zhao,et al.  Effect of ISM1 on the Immune Microenvironment and Epithelial-Mesenchymal Transition in Colorectal Cancer , 2021, Frontiers in Cell and Developmental Biology.

[71]  Y. Wang,et al.  Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  Chune Yu,et al.  Linking Tumor Microenvironment to Plasticity of Cancer Stem Cells: Mechanisms and Application in Cancer Therapy , 2021, Frontiers in Oncology.

[73]  Athanasios Alexopoulos,et al.  Mechanisms. , 2021, Deutsches Arzteblatt international.

[74]  B. Broom,et al.  ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer , 2021, Clinical Cancer Research.

[75]  P. Khavari,et al.  Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics , 2021, Nature Reviews Genetics.

[76]  Benjamin Wu,et al.  Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region , 2021, Liver Cancer.

[77]  J. Ajani,et al.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial , 2021, The Lancet.

[78]  C. Berking,et al.  How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance , 2021, International journal of molecular sciences.

[79]  R. Fodde,et al.  Phenotypic plasticity underlies local invasion and distant metastasis in colon cancer , 2021, eLife.

[80]  K. Kelly,et al.  Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort , 2021, Targeted Oncology.

[81]  K. Tomczak,et al.  Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing , 2021, Proceedings of the National Academy of Sciences.

[82]  D. Dean,et al.  Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells , 2021, Science Advances.

[83]  R. Weinberg,et al.  Linking EMT programmes to normal and neoplastic epithelial stem cells , 2021, Nature Reviews Cancer.

[84]  T. Yau,et al.  Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study , 2021, Liver Cancer.

[85]  M. Abbaszadegan,et al.  Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC , 2021, Journal of Molecular Histology.

[86]  G. Abou-Alfa,et al.  Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma , 2021, Cancer medicine.

[87]  L. Ouyang,et al.  Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery. , 2021, Journal of medicinal chemistry.

[88]  S. Spencer,et al.  Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling , 2021, Nature Communications.

[89]  Qinglian He,et al.  Cancer stem cells in colorectal cancer and the association with chemotherapy resistance , 2021, Medical Oncology.

[90]  C. Paweletz,et al.  Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. , 2021, Cancer discovery.

[91]  Jue Fan,et al.  Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC , 2021, Frontiers in Oncology.

[92]  N. Sonenberg,et al.  Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses. , 2021, The Journal of clinical investigation.

[93]  E. Petretto,et al.  WNT inhibition creates a BRCA‐like state in Wnt‐addicted cancer , 2021, EMBO molecular medicine.

[94]  A. Varghese,et al.  Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer , 2021, Journal for ImmunoTherapy of Cancer.

[95]  S. H. Lee,et al.  Wnt/β-catenin/Slug pathway contributes to tumor invasion and lymph node metastasis in head and neck squamous cell carcinoma , 2021, Clinical & Experimental Metastasis.

[96]  Bin Zhang,et al.  Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis , 2021, Nature Communications.

[97]  Wenjie Zhu,et al.  Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate , 2021, Science Translational Medicine.

[98]  Shenglan Yang,et al.  EMT‐associated microRNAs and their roles in cancer stemness and drug resistance , 2021, Cancer communications.

[99]  James H. Fugett,et al.  Functional Hierarchy and Cooperation of EMT Master Transcription Factors in Breast Cancer Metastasis , 2021, Molecular Cancer Research.

[100]  K. Shen,et al.  miRNA-128 modulates bone neoplasms cells proliferation and migration through the WNT/β-catenin and EMT signal pathways , 2021, Journal of Orthopaedic Surgery and Research.

[101]  Yubin Zhou,et al.  Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. , 2021, Seminars in cancer biology.

[102]  K. Hosomichi,et al.  NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment , 2021, Translational lung cancer research.

[103]  A. Ben-Baruch,et al.  Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy , 2021, Frontiers in Oncology.

[104]  S. Patra,et al.  Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[105]  D. Matei,et al.  Methylomic Signatures of High Grade Serous Ovarian Cancer , 2020, Epigenetics.

[106]  Hai-hong Zhang,et al.  miRNA-490-3p promotes the metastatic progression of invasive ductal carcinoma , 2020, Oncology reports.

[107]  S. Salas,et al.  Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies , 2020, Journal for ImmunoTherapy of Cancer.

[108]  M. Hims,et al.  TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts , 2020, Nature Communications.

[109]  R. Hass,et al.  The Intimate Relationship among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes , 2020, Cancers.

[110]  Yang Zhang,et al.  Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer , 2020, Journal of Hematology & Oncology.

[111]  P. Zhou,et al.  MiRNA-155-5p inhibits epithelium-to-mesenchymal transition (EMT) by targeting GSK-3β during radiation-induced pulmonary fibrosis. , 2020, Archives of biochemistry and biophysics.

[112]  Dihua Yu,et al.  Tumor microenvironment as a therapeutic target in cancer. , 2020, Pharmacology & therapeutics.

[113]  M. Rubin,et al.  Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. , 2020, Molecular cell.

[114]  Soon Sung Kwon,et al.  Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells. , 2020, Cancer letters.

[115]  S. Batra,et al.  Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma , 2020, Oncogene.

[116]  Wen-quan Wang,et al.  Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma , 2020, Experimental Hematology & Oncology.

[117]  E. Nice,et al.  Emerging role of tumor cell plasticity in modifying therapeutic response , 2020, Signal Transduction and Targeted Therapy.

[118]  Kristen Fousek,et al.  Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. , 2020, Pharmacology & therapeutics.

[119]  Ying Cheng,et al.  Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials , 2020, Cancer.

[120]  A. Rustgi,et al.  EMT, MET, Plasticity, and Tumor Metastasis. , 2020, Trends in cell biology.

[121]  M. Simon,et al.  The tumor microenvironment , 2020, Current Biology.

[122]  H. Lenz,et al.  Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer , 2020, Clinical Cancer Research.

[123]  B. Weinstein,et al.  Live Imaging of Intracranial Lymphatics in the Zebrafish , 2020, bioRxiv.

[124]  Matthew J. Meiners,et al.  SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. , 2020, Cancer cell.

[125]  M. Kudo,et al.  Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer , 2020, Journal for immunotherapy of cancer.

[126]  H. Döhner,et al.  DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy , 2020, Scientific Data.

[127]  Kristen Fousek,et al.  Tumor Plasticity and Resistance to Immunotherapy. , 2020, Trends in cancer.

[128]  Ke Xu,et al.  Cinobufacini Inhibits Colon Cancer Invasion and Metastasis via Suppressing Wnt/β-Catenin Signaling Pathway and EMT. , 2020, The American journal of Chinese medicine.

[129]  G. Fanelli,et al.  Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization , 2020, Frontiers in Oncology.

[130]  L. Roshangar,et al.  Tumor microenvironment complexity and therapeutic implications at a glance , 2020, Cell Communication and Signaling.

[131]  P. Clemons,et al.  Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles , 2020, Nature Chemical Biology.

[132]  P. Hershberger,et al.  Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer , 2020, Frontiers in Genetics.

[133]  D. Pe’er,et al.  Lineage plasticity in cancer: a shared pathway of therapeutic resistance , 2020, Nature Reviews Clinical Oncology.

[134]  M. Rubin,et al.  Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity , 2020, Nature Communications.

[135]  D. Capper,et al.  Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma , 2020, Investigational New Drugs.

[136]  Zhi Zeng,et al.  SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway , 2020, Aging.

[137]  D. Stainier,et al.  Nfatc1 Promotes Interstitial Cell Formation During Cardiac Valve Development in Zebrafish , 2020, Circulation research.

[138]  Guo‐Jun Zhang,et al.  Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple‐negative breast cancer cells , 2020, International journal of cancer.

[139]  M. Ahn,et al.  TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[140]  S. Tomida,et al.  Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[141]  A. Giuliani,et al.  A pre-existing population of ZEB2+ quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer , 2020, Journal of Experimental & Clinical Cancer Research.

[142]  M. Czyz,et al.  Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity , 2020, Cells.

[143]  M. Jolly,et al.  Cancer Stem Cell Plasticity – A Deadly Deal , 2019, Frontiers in Molecular Biosciences.

[144]  Nicholas Panchy,et al.  Integrative Transcriptomic Analysis Reveals a Multiphasic Epithelial–Mesenchymal Spectrum in Cancer and Non-tumorigenic Cells , 2020, Frontiers in Oncology.

[145]  K. Skrzypek,et al.  Molecular mechanisms of epithelial to mesenchymal transition in tumor metastasis. , 2019, Acta biochimica Polonica.

[146]  A. Ravindranathan,et al.  Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration. , 2019, Cell stem cell.

[147]  J. Schlom,et al.  Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models , 2019, Clinical Cancer Research.

[148]  M. Grompe,et al.  In Vivo Lineage Tracing of Polyploid Hepatocytes Reveals Extensive Proliferation during Liver Regeneration. , 2019, Cell stem cell.

[149]  M. Giera,et al.  TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer , 2019, Cellular and Molecular Life Sciences.

[150]  I. Berindan‐Neagoe,et al.  Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes , 2019, International journal of molecular sciences.

[151]  Hongbin Wang,et al.  MicroRNA-181d-5p-Containing Exosomes Derived from CAFs Promote EMT by Regulating CDX2/HOXA5 in Breast Cancer , 2019, Molecular therapy. Nucleic acids.

[152]  Jih-Hsiang Lee,et al.  Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. , 2019, European journal of cancer.

[153]  N. Barlev,et al.  Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis , 2019, Cell Death & Disease.

[154]  T. Jiang,et al.  Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice. , 2019, Lung cancer.

[155]  O. Elemento,et al.  Clinical features of neuroendocrine prostate cancer. , 2019, European journal of cancer.

[156]  Xuan Zhu,et al.  EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies , 2019, Front. Oncol..

[157]  F. D. de Sauvage,et al.  The great escape: tumour cell plasticity in resistance to targeted therapy , 2019, Nature Reviews Drug Discovery.

[158]  J Zhang,et al.  MA11.06 A PII Study of Toripalimab, a PD-1 mAb, in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies , 2019, Journal of Thoracic Oncology.

[159]  F. Francescangeli,et al.  Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities , 2019, Cancers.

[160]  Ying Xie,et al.  Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma , 2019, Oncogene.

[161]  D. Pe’er,et al.  Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[162]  X. Guan,et al.  Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells. , 2019, American journal of cancer research.

[163]  G. Berchem,et al.  Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges , 2019, Cells.

[164]  E. Giovannetti,et al.  Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[165]  Z. Culig.  Epithelial mesenchymal transition and resistance in endocrine-related cancers. , 2019, Biochimica et biophysica acta. Molecular cell research.

[166]  Xiaozhen Liu,et al.  EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies , 2019, International journal of cancer.

[167]  G. Berchem,et al.  Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. , 2019, Cancer letters.

[168]  R. Cetin-Atalay,et al.  Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment , 2019, Molecular Cancer Therapeutics.

[169]  G. Nasti,et al.  Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms , 2019, Journal of clinical medicine.

[170]  M. Najafi,et al.  Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance. , 2019, Life sciences.

[171]  B. Ramaswamy,et al.  The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer? , 2019, Cancers.

[172]  R. Aebersold,et al.  Proteomic identification of a marker signature for MAPKi resistance in melanoma , 2019, The EMBO journal.

[173]  R. Burger,et al.  A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. , 2019, Gynecologic oncology.

[174]  P. Galle,et al.  A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma , 2019, Clinical and translational gastroenterology.

[175]  T. Graeber,et al.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. , 2019, Cancer cell.

[176]  A. Jeong,et al.  Highlighted STAT3 as a potential drug target for cancer therapy , 2019, BMB reports.

[177]  Xiaozhuo Chen,et al.  Drug resistance and combating drug resistance in cancer , 2019, Cancer drug resistance.

[178]  H. Xing,et al.  Asymmetric Division Gene Neurl2 Mediates Twist2 Regulation of Self-Renewal of Mouse Lewis Lung Cancer Stem Cells , 2019, Journal of Cancer.

[179]  P. ten Dijke,et al.  TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis , 2019, International journal of molecular sciences.

[180]  J. Cortes,et al.  Hedgehog signaling inhibitors in solid and hematological cancers. , 2019, Cancer treatment reviews.

[181]  Jiandang Shi,et al.  Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer , 2019, Cell Communication and Signaling.

[182]  Joshua M. Korn,et al.  Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer , 2019, Oncogene.

[183]  Jiandang Shi,et al.  Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer , 2019, Cell Communication and Signaling.

[184]  M. Ebert,et al.  MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer , 2019, Nature Communications.

[185]  G. Moreno-Bueno,et al.  Contribution of Epithelial Plasticity to Therapy Resistance , 2019, Journal of clinical medicine.

[186]  M. Socinski,et al.  Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. , 2019, The Lancet. Respiratory medicine.

[187]  M. Kris,et al.  Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[188]  Sung Sook Lee,et al.  Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[189]  Ting Zhang,et al.  The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling , 2019, Cell Death & Disease.

[190]  F. Azuaje,et al.  Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment , 2019, Nature Communications.

[191]  J. Schlom,et al.  Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. , 2019, JCI insight.

[192]  Yibin Kang,et al.  Bone Vascular Niche E-selectin Induces Mesenchymal-Epithelial Transition and Wnt Activation in Cancer Cells to Promote Bone Metastasis , 2019, Nature Cell Biology.

[193]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[194]  Christian M. Metallo,et al.  Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. , 2019, Cancer cell.

[195]  A. Sureda,et al.  Targeting Hedgehog signaling pathway: Paving the road for cancer therapy , 2019, Pharmacological research.

[196]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[197]  K. Shokat,et al.  Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition , 2019, Science Signaling.

[198]  Siling Wang,et al.  Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade , 2019, Advanced materials.

[199]  M. Mino‐Kenudson,et al.  EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  T. Greten,et al.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. , 2019, Gastroenterology.

[201]  N. Girard,et al.  A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[202]  Ximing J. Yang,et al.  Targeting FOXA1-mediated repression of TGF-&bgr; signaling suppresses castration-resistant prostate cancer progression , 2018, The Journal of clinical investigation.

[203]  Brian C. Jackson,et al.  Wnt signaling dynamics in head and neck squamous cell cancer tumor‐stroma interactions , 2018, Molecular carcinogenesis.

[204]  Jianping Bai,et al.  miR-30a regulates the proliferation and invasion of breast cancer cells by targeting Snail. , 2018, Oncology letters.

[205]  Xiaoyan Zhang,et al.  Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation , 2018, Journal of cellular physiology.

[206]  S. Elahi,et al.  CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-β , 2018, PLoS biology.

[207]  J. Soh,et al.  Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells , 2018, Molecular Cancer Research.

[208]  Atique U. Ahmed,et al.  Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma , 2018, Cell Death and Disease.

[209]  Wei-long Zhong,et al.  Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway , 2018, EBioMedicine.

[210]  Benjamin L Ebert,et al.  Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN , 2018, Science.

[211]  J. Tabernero,et al.  Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer , 2018, British Journal of Cancer.

[212]  J. Tabernero,et al.  A slow-cycling Lgr5 tumour population mediates basal cell carcinoma relapse after therapy , 2018, Nature.

[213]  F. Peale,et al.  A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition , 2018, Nature.

[214]  S. Law,et al.  Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. , 2018, The international journal of biochemistry & cell biology.

[215]  C. Leung,et al.  Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy. , 2018, Angewandte Chemie.

[216]  A. Turnbull,et al.  Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours , 2018, Breast Cancer Research.

[217]  T. Reya,et al.  Stem cell fate in cancer growth, progression and therapy resistance , 2018, Nature Reviews Cancer.

[218]  N. Nonomura,et al.  Role of Androgen Receptor in Prostate Cancer: A Review , 2018, The world journal of men's health.

[219]  K. Akashi,et al.  Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer , 2018, Oncogene.

[220]  E. Giroux-Leprieur,et al.  Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance , 2018, International journal of molecular sciences.

[221]  Ming O. Li,et al.  TGF‐β Control of Adaptive Immune Tolerance: A Break From Treg Cells , 2018, BioEssays : news and reviews in molecular, cellular and developmental biology.

[222]  E. Giannoni,et al.  Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. , 2018, Cell metabolism.

[223]  C. Rudin,et al.  Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer , 2018, Oncogene.

[224]  K. Flaherty,et al.  Toward Minimal Residual Disease-Directed Therapy in Melanoma , 2018, Cell.

[225]  Tetsuya Tanimoto,et al.  EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[226]  F. Rojo,et al.  Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer , 2018, Nature Communications.

[227]  Levi A Garraway,et al.  A Convergence-Based Framework for Cancer Drug Resistance. , 2018, Cancer cell.

[228]  L. Fagnocchi,et al.  Tumorigenic Cell Reprogramming and Cancer Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics , 2018, Stem cells international.

[229]  Kari A. Huppert,et al.  De novo formation of the biliary system by TGFβ-mediated hepatocyte transdifferentiation , 2018, Nature.

[230]  H. Shan,et al.  YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD , 2018, Cell Death & Disease.

[231]  T. Voet,et al.  Identification of the tumour transition states occurring during EMT , 2018, Nature.

[232]  Andrew R. Morton,et al.  Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. , 2018, Cell stem cell.

[233]  Xiguang Chen,et al.  Axl inhibitors as novel cancer therapeutic agents. , 2018, Life sciences.

[234]  Qian Li,et al.  Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential , 2018, Biomarker Research.

[235]  M. Shen,et al.  Lineage Plasticity in Cancer Progression and Treatment. , 2018, Annual review of cancer biology.

[236]  C. Mitsiades,et al.  Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions , 2018, Cancer Immunology, Immunotherapy.

[237]  K. Smolderen.  Clinical implications and future perspectives , 2018, ESC CardioMed.

[238]  Q. Yan,et al.  Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and stemness. , 2018, Cancer letters.

[239]  A. Zoubeidi,et al.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer , 2018, Nature Reviews Urology.

[240]  M. Sadar,et al.  Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens , 2018, Research and reports in urology.

[241]  Rui Zhang,et al.  Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells , 2018, Oncoimmunology.

[242]  J. Schlom,et al.  M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine , 2018, Oncoimmunology.

[243]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[244]  H. Yao,et al.  CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness , 2018, Cell.

[245]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[246]  Aroop Sircar,et al.  Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β , 2018, Science Translational Medicine.

[247]  Xinyu R. Ma,et al.  Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma , 2018, Medicine.

[248]  Xiaohong Xu,et al.  Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor , 2017, Oncotarget.

[249]  A. Virós,et al.  Mechanisms of Drug Resistance in Melanoma. , 2017, Handbook of experimental pharmacology.

[250]  A. Zhavoronkov,et al.  Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy , 2018, Nature Communications.

[251]  Jianchang Yang.  SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis , 2018, Biomarker Research.

[252]  D. Stroncek,et al.  Mesenchymal stromal cell plasticity and the tumor microenvironment. , 2017, Emerging topics in life sciences.

[253]  J. Rajagopal,et al.  The epigenetic basis of cellular plasticity. , 2017, Current opinion in cell biology.

[254]  J. Utikal,et al.  New role of ID3 in melanoma adaptive drug-resistance , 2017, Oncotarget.

[255]  A. Bass,et al.  Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma , 2017, Nature Communications.

[256]  S. Corso,et al.  YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC , 2017, Neoplasia.

[257]  Kristen K. McCampbell,et al.  Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. , 2017, JCI insight.

[258]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[259]  N. Sharifi,et al.  Androgen Signaling in Prostate Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[260]  M. Lewis,et al.  New paradigms for the Hedgehog signaling network in mammary gland development and breast Cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[261]  Chih-Jen Yang,et al.  Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells , 2017, PloS one.

[262]  M. Rubin,et al.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. , 2017, Cancer discovery.

[263]  T. Mitsudomi,et al.  Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[264]  Stuart L. Schreiber,et al.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.

[265]  F. Portillo,et al.  EMT: Present and future in clinical oncology , 2017, Molecular oncology.

[266]  R. Huang,et al.  The EMT spectrum and therapeutic opportunities , 2017, Molecular oncology.

[267]  Sydney M. Shaffer,et al.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.

[268]  P. Park,et al.  Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[269]  G. Mills,et al.  Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo , 2017, npj Breast Cancer.

[270]  Francisco J. Sánchez-Rivera,et al.  A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma , 2017, Nature.

[271]  C. Wells,et al.  Mural lymphatic endothelial cells regulate meningeal angiogenesis in the zebrafish , 2017, Nature Neuroscience.

[272]  C. Pilarsky,et al.  The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer , 2017, Nature Cell Biology.

[273]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[274]  R. Weinberg,et al.  Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. , 2017, Cancer research.

[275]  Antonina V. Kurtova,et al.  A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer , 2017, Nature.

[276]  J. Ahn,et al.  EGFR TKI combination with immunotherapy in non-small cell lung cancer , 2017, Expert opinion on drug safety.

[277]  J. Medema,et al.  Intra-tumor heterogeneity from a cancer stem cell perspective , 2017, Molecular Cancer.

[278]  Shawn M. Gillespie,et al.  Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. , 2017, Cell stem cell.

[279]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[280]  James S. Duncan,et al.  Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. , 2017, Cancer discovery.

[281]  B. Samten,et al.  Early Secreted Antigenic Target of 6-kDa of Mycobacterium tuberculosis Stimulates IL-6 Production by Macrophages through Activation of STAT3 , 2017, Scientific Reports.

[282]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[283]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[284]  A. Koong,et al.  Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies , 2017, The Journal of clinical investigation.

[285]  E. Raymond,et al.  Novel TGF-β inhibitors ready for prime time in onco-immunology , 2016, Oncoimmunology.

[286]  P. ten Dijke,et al.  Targeting TGF-β Signaling in Cancer. , 2017, Trends in cancer.

[287]  N. Radosevic-Robin,et al.  Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis , 2016, Clinical Cancer Research.

[288]  Young A Kim,et al.  PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. , 2016, Human pathology.

[289]  G. Gildengorin,et al.  Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2016, The Lancet. Oncology.

[290]  P. Pelicci,et al.  Molecular mechanisms of asymmetric divisions in mammary stem cells , 2016, EMBO reports.

[291]  J. Rajagopal,et al.  Cellular plasticity: 1712 to the present day. , 2016, Current opinion in cell biology.

[292]  Jon R. Wilson,et al.  Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymp , 2016, Journal of medicinal chemistry.

[293]  Kaitlyn M. Gayvert,et al.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.

[294]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[295]  M. Okumura,et al.  IL‐6 Secreted from Cancer‐Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial‐Mesenchymal Transition Signaling , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[296]  G. Taylor,et al.  Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture , 2016, Gut.

[297]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[298]  R. Prinjha,et al.  Structural analysis of human KDM5B guides histone demethylase inhibitor development. , 2016, Nature chemical biology.

[299]  C. Allis,et al.  The molecular hallmarks of epigenetic control , 2016, Nature Reviews Genetics.

[300]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[301]  Kristen K. McCampbell,et al.  IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib , 2016, Oncotarget.

[302]  F. Sotgia,et al.  Cancer stem cell metabolism , 2016, Breast Cancer Research.

[303]  T. Das,et al.  Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. , 2016, Cancer research.

[304]  B. Stanger,et al.  Adult cell plasticity in vivo: de-differentiation and transdifferentiation are back in style , 2016, Nature Reviews Molecular Cell Biology.

[305]  Robert A. Weinberg,et al.  Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability , 2016, Science.

[306]  Bruce A. Posner,et al.  Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.

[307]  David K. Finlay,et al.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway , 2016, Science Signaling.

[308]  S. Dedhar,et al.  Targeting hypoxic response for cancer therapy , 2016, Oncotarget.

[309]  Jing Wang,et al.  Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[310]  M. Jackson,et al.  Cancer Stem Cell Plasticity Drives Therapeutic Resistance , 2016, Cancers.

[311]  Asier Unciti-Broceta,et al.  AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective. , 2015, Journal of medicinal chemistry.

[312]  T. Mitsudomi,et al.  Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. , 2016, Lung cancer.

[313]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[314]  S. Woo,et al.  CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer , 2015, PloS one.

[315]  David Gilligan,et al.  Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. , 2015, The Lancet. Oncology.

[316]  Matt Trau,et al.  DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer , 2015, Nature Communications.

[317]  N. Lu,et al.  A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition , 2015, Cell adhesion & migration.

[318]  J. Hou,et al.  A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. , 2015, Journal of the American Academy of Dermatology.

[319]  Manran Liu,et al.  Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. , 2015, Cancer letters.

[320]  L. Sequist,et al.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. , 2015, The Lancet. Oncology.

[321]  Qingqing Zhu,et al.  The role of TWIST1 in epithelial-mesenchymal transition and cancers , 2015, Tumor Biology.

[322]  Duan Ma,et al.  The SNAI1 3′UTR functions as a sponge for multiple migration-/invasion-related microRNAs , 2015, Tumor Biology.

[323]  H P Soyer,et al.  A stress-induced early innate response causes multidrug tolerance in melanoma , 2014, Oncogene.

[324]  A. Walch,et al.  Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice , 2014, Nature Cell Biology.

[325]  Kristian Helin,et al.  Inhibition of demethylases by GSK-J1/J4 , 2014, Nature.

[326]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[327]  Jianqiu Chen,et al.  Slug overexpression induces stemness and promotes hepatocellular carcinoma cell invasion and metastasis , 2014, Oncology letters.

[328]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[329]  Christopher J. Ott,et al.  An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.

[330]  Tim J. Wigle,et al.  Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.

[331]  D. Milewicz,et al.  IL‐6 Regulates Extracellular Matrix Remodeling Associated With Aortic Dilation in a Fibrillin‐1 Hypomorphic mgR/mgR Mouse Model of Severe Marfan Syndrome , 2014, Journal of the American Heart Association.

[332]  Yu-mei Feng,et al.  Cancer-associated fibroblasts induce epithelial–mesenchymal transition of breast cancer cells through paracrine TGF-β signalling , 2013, British Journal of Cancer.

[333]  C. Collins,et al.  REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer , 2013, Nucleic acids research.

[334]  P. Song,et al.  CLINICAL OUTCOMES? , 2014 .

[335]  W. Sellers,et al.  Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974 , 2013, Proceedings of the National Academy of Sciences.

[336]  J. Wolchok,et al.  Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.

[337]  W Abou-Kheir,et al.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms , 2013, Oncogene.

[338]  Pengyuan Yang,et al.  Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis. , 2012, The international journal of biochemistry & cell biology.

[339]  W. Woodward,et al.  Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β‐Catenin Signaling , 2012, Stem cells.

[340]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[341]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[342]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[343]  Christopher J. Schofield,et al.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.

[344]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[345]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[346]  Li Ma,et al.  MicroRNA control of epithelial–mesenchymal transition and metastasis , 2012, Cancer and Metastasis Reviews.

[347]  A. Richardson,et al.  Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. , 2012, Free radical biology & medicine.

[348]  Jun-ling Liu,et al.  Activation of notch‐1 enhances epithelial–mesenchymal transition in gefitinib‐acquired resistant lung cancer cells , 2012, Journal of cellular biochemistry.

[349]  D. Gray,et al.  B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells , 2012, The Journal of experimental medicine.

[350]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[351]  Martin J. Aryee,et al.  A DNA hypermethylation module for the stem/progenitor cell signature of cancer , 2011, Genome research.

[352]  A. Menssen,et al.  miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions , 2011, Cell cycle.

[353]  J. Bertrand,et al.  Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells , 2011, Leukemia.

[354]  H. Uramoto,et al.  Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. , 2011, Lung cancer.

[355]  R. M. Simpson,et al.  Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. , 2011, The American journal of pathology.

[356]  A. Rangarajan,et al.  Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters , 2011, Cell Death and Disease.

[357]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[358]  J. Shih,et al.  Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. , 2011, American journal of respiratory and critical care medicine.

[359]  S. Morrison,et al.  Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.

[360]  C. Pollock,et al.  Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor. , 2010, The international journal of biochemistry & cell biology.

[361]  A. Merchant,et al.  Targeting Hedgehog — a Cancer Stem Cell Pathway , 2010, Clinical Cancer Research.

[362]  Irving L. Weissman,et al.  Human Melanoma Initiating Cells Express Neural Crest Nerve Growth Factor Receptor CD271 , 2010, Nature.

[363]  Louis Vermeulen,et al.  Wnt activity defines colon cancer stem cells and is regulated by the microenvironment , 2010, Nature Cell Biology.

[364]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[365]  C. Brennan,et al.  Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. , 2010, Cell stem cell.

[366]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[367]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[368]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[369]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[370]  Tannishtha Reya,et al.  Imaging hematopoietic precursor division in real time. , 2007, Cell stem cell.

[371]  Jing Qing,et al.  TGF‐β activates Erk MAP kinase signalling through direct phosphorylation of ShcA , 2007 .

[372]  Jing Qing,et al.  TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. , 2007, The EMBO journal.

[373]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[374]  D. Elder,et al.  A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.

[375]  M. Goodell,et al.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[376]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[377]  M. Fukuoka,et al.  Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[378]  L. R. Howe,et al.  Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. , 2003, Cancer research.

[379]  G. Bubley,et al.  Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor* , 2002, The Journal of Biological Chemistry.

[380]  D. Tindall,et al.  The role of the androgen receptor in prostate cancer. , 2002, Critical reviews in eukaryotic gene expression.

[381]  P. Glazer,et al.  Genetic instability induced by the tumor microenvironment. , 1996, Cancer research.

[382]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[383]  N. Dubin.  Mathematical Model , 2022 .

[384]  C. Waddington.  Embryology, Epigenetics and Biogenetics , 1956, Nature.